Bluebird bio Receives US FDA Nod for Sickle Cell Therapy


The US Food and Drug Administration (FDA) has approved bluebird’s Lyfgenia (lovotibeglogene autotemcel) for the treatment of sickle cell disease. Approved for patients aged 12 or older with a history of vaso-occlusive events (VOEs), Lyfgenia is a one-time gene therapy with the potential to resolve VOEs and is custom-designed to treat the underlying cause of the disease. The firm plans to make the therapy available by early 2024.

The sickle cell therapy, Lyfgenia, also known as lovo-cell will be available at the firm’s established network of qualified treatment centers (QTCs). As per the firm, these centers specialize in administering complex gene therapies.